MEDtalk: KEYNOTE 590 will change practice for patients with oesophagus Cancer
Ken Kato | Syys 2020 | | ESMO20
The KEYNOTE 590 trial examined first-line chemotherapy, with or without pembrolizumab, in patients with squamous cell carcinoma of the oesophagus, adenocarcinoma of the oesophagus, or Siewert type 1 gastro-oesophageal junction adenocarcinoma. In this MEDtalk Ken Kato, MD. PhD, National Cancer Center Hospital, Tokyo, presents the results of the KEYNOTE 590 study.